Modified Nucleic Acids Enhance PAH Enzyme Activity for PKU Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for phenylketonuria (PKU) and hyperphenylalaninemia, such as dietary restrictions and BH4 supplementation, have limitations, particularly for severe forms, and there is a need for more effective treatments that enhance phenylalanine hydroxylase (PAH) activity to manage elevated phenylalanine levels.
Innovation Solution
Modified nucleic acids, including HULC and Pair mimics with 2′-fluoro base modifications and phosphorothioate bonds, are used to increase the affinity of PAH for its substrate and cofactor, administered via nanoparticles to enhance enzymatic conversion of phenylalanine to tyrosine, potentially combined with existing therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary restrictions and BH4 supplementation are used to treat PKU, then blood phenylalanine levels are controlled, but quality of life is significantly impacted and treatment effectiveness is limited for severe cases
Solution Approach 1:
The patent introduces modified nucleic acids (HULC and Pair mimics) as intermediary molecules that mediate between the existing PAH enzyme and its substrates. These modified nucleic acids bind to PAH and enhance its catalytic activity, serving as a mediator that improves enzyme function without requiring dietary restrictions or cofactor supplementation.
Solution Approach 2:
The patent applies parameter changes by modifying the nucleic acid structure (using 2'-fluoro modifications and phosphorothioate bonds) to enhance stability and binding affinity. It also changes the enzymatic parameters of PAH by increasing substrate and cofactor affinity, thereby improving treatment effectiveness without impacting quality of life.
2Productivity
If enzyme supplementation therapy is used to treat severe PKU, then phenylalanine clearance is improved, but immunogenicity issues arise
Solution Approach 1:
Instead of using exogenous enzyme supplementation that triggers immune responses, the patent uses modified nucleic acids that copy and enhance the function of the patient's own PAH enzyme. The HULC and Pair mimics are designed to replicate the natural activating mechanism of PAH, thereby improving phenylalanine clearance without introducing foreign proteins that could be immunogenic.
3Duration of action of stationary object
If gene therapy is used to correct PAH mutations, then long-term treatment potential is achieved, but uncertainty and safety concerns remain
Solution Approach 1:
The patent uses transient modified nucleic acids rather than permanent gene therapy approaches. The modified HULC and Pair mimics are designed to be temporary, non-integrating molecules that provide sustained but reversible enzyme activation. This approach achieves long-term treatment effects without the safety concerns of viral vector integration and permanent genetic modification.
4Productivity
If PAH enzyme activity is enhanced through modified nucleic acids, then phenylalanine to tyrosine conversion is improved, but molecular complexity of the treatment increases
Solution Approach 1:
The patent creates composite molecular structures by combining modified nucleic acid sequences (HULC and Pair mimics) with the PAH enzyme system. The modified nucleic acids contain composite chemical modifications (2'-fluoro sugars and phosphorothioate bonds) that work together synergistically to enhance stability and binding, thereby improving conversion efficiency while managing molecular complexity through rational design.
Data Source
AI summary
This disclosure provides modified nucleic acids and compositions thereof that are able to mimic the human HULC lncRNA and/or the mouse Pair lncRNA and enhance phenylalanine hydroxylase enzyme (PAH)-substrate binding affinity, PAH-cofactor binding affinity, and/or PAH enzymatic conversion of phenylalanine to tyrosine. Also provided are methods of using the modified nucleic acids and compositions thereof to treat subjects having or suspected of having phenylketonuria and hyperphenylalaninemia.